BOSTON SCIENTIFIC CORP (BSX) Stock Fundamental Analysis
USA - NYSE:BSX - US1011371077 - Common Stock
101.495 USD
-0.27 (-0.26%)
Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. BSX scores excellent on profitability, but there are some minor concerns on its financial health. BSX is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
In the past year BSX was profitable.
In the past year BSX had a positive cash flow from operations.
Of the past 5 years BSX 4 years were profitable.
In the past 5 years BSX always reported a positive cash flow from operatings.
1.2 Ratios
BSX has a better Return On Assets (6.54%) than 85.64% of its industry peers.
The Return On Equity of BSX (11.93%) is better than 87.23% of its industry peers.
The Return On Invested Capital of BSX (8.09%) is better than 85.11% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSX is below the industry average of 8.98%.
The last Return On Invested Capital (8.09%) for BSX is above the 3 year average (6.59%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROIC | 8.09% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
1.3 Margins
BSX has a Profit Margin of 14.42%. This is amongst the best in the industry. BSX outperforms 89.89% of its industry peers.
BSX's Profit Margin has declined in the last couple of years.
BSX has a Operating Margin of 19.40%. This is amongst the best in the industry. BSX outperforms 92.02% of its industry peers.
In the last couple of years the Operating Margin of BSX has remained more or less at the same level.
The Gross Margin of BSX (68.57%) is better than 76.06% of its industry peers.
In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% |
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BSX has been increased compared to 1 year ago.
The number of shares outstanding for BSX has been increased compared to 5 years ago.
The debt/assets ratio for BSX is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.66 indicates that BSX is not in any danger for bankruptcy at the moment.
The Altman-Z score of BSX (5.66) is better than 79.79% of its industry peers.
The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
BSX has a Debt to FCF ratio of 3.03. This is amongst the best in the industry. BSX outperforms 84.57% of its industry peers.
BSX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
BSX's Debt to Equity ratio of 0.48 is in line compared to the rest of the industry. BSX outperforms 44.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 5.66 |
ROIC/WACC0.97
WACC8.36%
2.3 Liquidity
A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
The Current ratio of BSX (1.51) is worse than 75.53% of its industry peers.
A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
BSX's Quick ratio of 0.96 is on the low side compared to the rest of the industry. BSX is outperformed by 79.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 25.00% over the past year.
Measured over the past years, BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
The Revenue has grown by 21.62% in the past year. This is a very strong growth!
BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.30% yearly.
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
3.2 Future
Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.01% on average per year.
Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 12.51% on average per year.
EPS Next Y22.11%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 34.41, BSX can be considered very expensive at the moment.
BSX's Price/Earnings ratio is a bit cheaper when compared to the industry. BSX is cheaper than 71.28% of the companies in the same industry.
When comparing the Price/Earnings ratio of BSX to the average of the S&P500 Index (25.56), we can say BSX is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 29.01, the valuation of BSX can be described as expensive.
71.81% of the companies in the same industry are more expensive than BSX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 34.62. BSX is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.41 | ||
| Fwd PE | 29.01 |
4.2 Price Multiples
70.74% of the companies in the same industry are more expensive than BSX, based on the Enterprise Value to EBITDA ratio.
75.00% of the companies in the same industry are more expensive than BSX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 39.34 | ||
| EV/EBITDA | 31.56 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of BSX may justify a higher PE ratio.
A more expensive valuation may be justified as BSX's earnings are expected to grow with 16.46% in the coming years.
PEG (NY)1.56
PEG (5Y)3.6
EPS Next 2Y18.06%
EPS Next 3Y16.46%
5. Dividend
5.1 Amount
No dividends for BSX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BSX (11/18/2025, 9:41:07 AM)
101.495
-0.27 (-0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner Change0.1%
Ins Owners0.15%
Ins Owner Change-3.61%
Market Cap150.39B
Revenue(TTM)19.35B
Net Income(TTM)2.79B
Analysts86.34
Price Target127.97 (26.09%)
Short Float %1.32%
Short Ratio2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)1.36%
PT rev (3m)1.75%
EPS NQ rev (1m)2.29%
EPS NQ rev (3m)2.28%
EPS NY rev (1m)1.77%
EPS NY rev (3m)3.98%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)2.15%
Revenue NY rev (1m)0.99%
Revenue NY rev (3m)1.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.41 | ||
| Fwd PE | 29.01 | ||
| P/S | 7.77 | ||
| P/FCF | 39.34 | ||
| P/OCF | 32.52 | ||
| P/B | 6.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 31.56 |
EPS(TTM)2.95
EY2.91%
EPS(NY)3.5
Fwd EY3.45%
FCF(TTM)2.58
FCFY2.54%
OCF(TTM)3.12
OCFY3.08%
SpS13.06
BVpS15.79
TBVpS-1.34
PEG (NY)1.56
PEG (5Y)3.6
Graham Number32.37
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 11.93% | ||
| ROCE | 10.04% | ||
| ROIC | 8.09% | ||
| ROICexc | 8.38% | ||
| ROICexgc | 28.19% | ||
| OM | 19.4% | ||
| PM (TTM) | 14.42% | ||
| GM | 68.57% | ||
| FCFM | 19.76% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.18 | ||
| Cap/Depr | 59.36% | ||
| Cap/Sales | 4.14% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.6% | ||
| Profit Quality | 136.98% | ||
| Current Ratio | 1.51 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 5.66 |
F-Score6
WACC8.36%
ROIC/WACC0.97
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%19.05%
EPS Next Y22.11%
EPS Next 2Y18.06%
EPS Next 3Y16.46%
EPS Next 5Y15.01%
Revenue 1Y (TTM)21.62%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%20.34%
Revenue Next Year20.9%
Revenue Next 2Y16.08%
Revenue Next 3Y14.18%
Revenue Next 5Y12.51%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.37%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / BSX FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX) stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSX.
What is the valuation status of BOSTON SCIENTIFIC CORP (BSX) stock?
ChartMill assigns a valuation rating of 4 / 10 to BOSTON SCIENTIFIC CORP (BSX). This can be considered as Fairly Valued.
How profitable is BOSTON SCIENTIFIC CORP (BSX) stock?
BOSTON SCIENTIFIC CORP (BSX) has a profitability rating of 7 / 10.
Can you provide the financial health for BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (BSX) is 4 / 10.
What is the expected EPS growth for BOSTON SCIENTIFIC CORP (BSX) stock?
The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 22.11% in the next year.